Batel Medical's Matrix Super™ Peripheral Constrained Balloon Receives NMPA Approval: China's First Domestic Constrained Balloon with Extensive Sizing Options
Barty Medical
Vascular Interventional and Implantable Device R&D Manufacturer
First Domestic Model, Rich in Variety
Better meet the comprehensive treatment needs of Chinese patients
On December 7, 2023, Matrix Super™, a peripherally constrained balloon dilation catheter independently developed by Barty Medical, was approved for marketing by the National Medical Products Administration (hereinafter referred to as "NMPA"). As China's first domestically produced peripherally constrained balloon, Matrix Super™ marks a breakthrough from zero in domestic production, further showcasing Barty Medical’s strong product development capabilities in the field of peripheral vascular intervention. This milestone signifies another significant step forward for Barty Medical on its path of innovation and progress. Matrix Super™ will bring unprecedented treatment options to peripheral vascular intervention.
In recent years, the clinical benefits and treatment philosophy of the "intervention without implant" therapy have gained increasing recognition, and the usage of peripheral drug-coated balloons has been growing. However, there are still some pain points in the use of drug-coated balloons. For example, during the vessel preparation process, uncontrolled torsional shear forces, longitudinal forces, and axial expansion forces generated by PTA balloon dilation can cause uncontrollable tears in the vessel wall, leading to flow-limiting dissections and the need for implantation of remedial stents.
Innovation originates from clinical practice, and products serve clinical needs. Barty Medical has chosen to address clinical pain points directly by developing the Matrix Super™ Peripheral Constrained Balloon. The Matrix Super™ Peripheral Constrained Balloon features a layer of nickel-titanium memory alloy metal mesh structure on the surface of a semi-compliant balloon. Under the constraint of the metal mesh, the balloon can achieve controlled, uniform, and non-traumatic expansion to modify and remodel plaques while reducing damage to the vascular wall. It also minimizes shear stress, achieves uniform and consistent inflation, rapid deflation, effectively reduces the occurrence of flow-limiting dissections and the implantation of remedial stents, creating favorable conditions for subsequent use of drug-coated balloons. Matrix Super™ Peripheral Constrained Balloon SpecificationsA rich variety of models, totaling 204 types, can better comprehensively meet the needs of patients in China.The treatment requires the only constrained balloon system that provides full guidewires of 14, 18, and 35, and is also the only constrained balloon available in lengths of 150mm and 200mm, allowing the advantage of "intervention without implantation" to benefit a wider range of patients.
The successful launch of Matrix Super™ has broken the monopoly of imported products and achieved a breakthrough from zero for domestically produced products, providing a brand-new solution for peripheral vascular intervention and opening a new chapter.
Barty Medical
Zhejiang Barty Medical Technology Co., Ltd. was established in August 2015. It is a national high-tech enterprise that integrates the research, development, production, and sales of high-end medical devices in the vascular intervention field. Barty Medical provides comprehensive solutions in the peripheral vascular intervention field. Its current product portfolio for clinical applications includes: Matrix Super™ Peripheral Constrained Balloon, Hetto Guiding Sheath, Huangtai Standard and High-Pressure Balloons, Hetto Femoral Sheath, Lutai Angiography Catheter, and Litai Guiding Catheter, among others. In the future, the company will launch a series of significant products, such as peripheral drug-coated balloons, peripheral constrained drug-coated balloons, and thrombectomy systems, offering doctors more advanced tools, safeguarding patients' health, and allowing medical technology to shine as a beacon of life!
Copyright Statement: This platform aims to help healthcare professionals better understand the latest advancements in relevant disease areas. The information published on this platform does not imply agreement with the descriptions and viewpoints presented; it is solely for providing more information. If there are any copyright issues, we kindly request the rights holders to contact us, and we will address them as soon as possible. This information is intended exclusively for healthcare professionals to stay informed, and such information should not replace professional medical guidance in any way, nor should it be considered as diagnostic or treatment advice. If such information is used for purposes other than staying informed, this platform and its authors assume no related responsibility.Contact email for cooperation:vascular@edoctor.cn。
